Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H37N5O10.H2O4S |
Molecular Weight | 581.592 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.[H][C@]3(O[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O[C@@]2([H])O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O)[C@H]1O)O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3N
InChI
InChIKey=YGTPKDKJVZOVCO-KELBJJLKSA-N
InChI=1S/C18H37N5O10.H2O4S/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18;1-5(2,3)4/h4-18,24-29H,1-3,19-23H2;(H2,1,2,3,4)/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+;/m0./s1
Molecular Formula | H2O4S |
Molecular Weight | 98.078 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C18H37N5O10 |
Molecular Weight | 483.5139 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: www.drugfuture.com/mt/bekanamycin-sulfate.pdfCurator's Comment: description was created based on several sources, including:
http://www.drugfuture.com/chemdata/Kanamycin.html
https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000902_022729_FI.pdf&retry=0&sys=m0b1l3
Sources: www.drugfuture.com/mt/bekanamycin-sulfate.pdf
Curator's Comment: description was created based on several sources, including:
http://www.drugfuture.com/chemdata/Kanamycin.html
https://farmaci.agenziafarmaco.gov.it/aifa/servlet/PdfDownloadServlet?pdfFileName=footer_000902_022729_FI.pdf&retry=0&sys=m0b1l3
Bekanamycin is an aminoglycoside and is a congener of kanamycin. It is given topically as the sulfate for the treatment of eye infections. It is reported
to be more toxic than kanamycin A. Antibiotic complex produced by Streptomyces kanamyceticus Okami & Umezawa from Japanese soil. There are no known interactions with other drugs.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11459219 |
180.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Visucloben antibiotico Approved UseIt is used in the treatment of eye infections. |
PubMed
Title | Date | PubMed |
---|---|---|
[Comparative studies on the problem of nephrotoxicity of the aminoglycosides: kanamycin, amikacin, butirosin and kanendomycin]. | 1976 |
|
In vitro and in vivo susceptibility of atypical mycobacteria to various drugs. | 1981 Sep-Oct |
|
Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. | 1993 Sep 24 |
|
Antimycobacterial activity of phorbol esters from the fruits of Sapium indicum. | 2003 Apr |
|
In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosis. | 2013 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://imedi.it/visucloben-antibiotico
One drop 4 times per day
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26592740
B. subtilis 168 (strain I) and S. epidermidis ATCC 12228 (strain X) are both susceptible to Bekanamycin (MIC = 4 ug/mL and 0.5 ug/mL, respectively).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:25:54 GMT 2023
by
admin
on
Fri Dec 15 15:25:54 GMT 2023
|
Record UNII |
KB71EA86HM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2363
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C001495
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
757787
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
KB71EA86HM
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
100000084993
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
SUB00687MIG
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
70550-99-1
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
SUPERSEDED | |||
|
636396
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
31255
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
DTXSID8048739
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
29701-07-3
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
m6599
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL2105594
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY | |||
|
C76153
Created by
admin on Fri Dec 15 15:25:54 GMT 2023 , Edited by admin on Fri Dec 15 15:25:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |